Lactic acid ( DrugBank: Lactic acid )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
265	Lipodystrophy	3
299	Cystic fibrosis	2

265. Lipodystrophy

---

Clinical trials : 116 /  Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00126308 (ClinicalTrials.gov)	November 2005	1/8/2005	Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy	A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)	HIV-Associated Lipodystrophy;HIV Infections	Device: poly-L-lactic acid	Kirby Institute	The University of New South Wales;Abbott;Bristol-Myers Squibb;Gilead Sciences;GlaxoSmithKline;Merck Sharp & Dohme Corp.;Hoffmann-La Roche;AIDS Council of New South Wales	Terminated	18 Years	N/A	Both	100	Phase 4	Australia
2	NCT00202228 (ClinicalTrials.gov)	July 2002	13/9/2005	Lactate Metabolism Study in HIV Infected Persons	Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.	HIV Infections;AIDS;Lactic Acidosis;Lipodystrophy	Drug: cofactor supplementation (thiamine, riboflavin, L-carnitine)	Queen's University	Ontario HIV Treatment Network	Completed	18 Years	N/A	Both	30	Phase 4	Canada
3	NCT00005764 (ClinicalTrials.gov)	May 2000	30/5/2000	A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients	Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)	HIV Infections;Lipodystrophy	Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine	Glaxo Wellcome	NULL	Completed	18 Years	N/A	Both	100	Phase 4	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-015875-28-IT (EUCTR)	07/10/2009	22/10/2009	Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic Fibrosis	Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic Fibrosis	infants with cystic fibrosis MedDRA version: 9.1;Level: SOC;Classification code 10017947 MedDRA version: 9.1;Classification code 10038738	INN or Proposed INN: Lactic acid producing organisms	UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
2	EUCTR2009-011289-27-IT (EUCTR)	22/04/2009	27/04/2009	Probiotics in Cystic Fibrosis - ND	Probiotics in Cystic Fibrosis - ND	Cystic Fibrosis Patients MedDRA version: 9.1;Level: SOC;Classification code 10017947	INN or Proposed INN: Lactic acid producing organisms	UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

Back to top